Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1372296 | Bioorganic & Medicinal Chemistry Letters | 2013 | 6 Pages |
Abstract
The potent and selective 3-amido-4-anilinoquinoline CSF-1R inhibitor AZ683 suffered from cardiovascular liabilities, which were linked to the off-target activities of the compound and ion channel activity in particular. Less basic and less lipophilic examples from both the quinoline and cinnoline series demonstrated cleaner secondary pharmacology profiles. Cinnoline 31 retained the required potency and oral PK profile, and was progressed through the safety screening cascade to be nominated into development as AZD7507.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
David A. Scott, Les A. Dakin, Kevin Daly, David J. Del Valle, R. Bruce Diebold, Lisa Drew, Jayachandran Ezhuthachan, Thomas W. Gero, Claude A. Ogoe, Charles A. Omer, Sean P. Redmond, Galina Repik, Kumar Thakur, Qing Ye, Xiaolan Zheng,